Hormonal regulation of p53 activity in mammary tissue

乳腺组织中 p53 活性的激素调节

基本信息

  • 批准号:
    7373562
  • 负责人:
  • 金额:
    $ 27.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The extreme risk of breast cancer among women bearing genetic deficiencies in the p53 pathway reveals the particular importance of p53 in breast cancer susceptibility. Our laboratory has demonstrated that the activity of the p53 tumor suppressor protein in the mammary epithelium is subject to hormonal regulation. Specifically, p53 activity is compromised in mammary epithelium of nulliparous mice, but is responsive to endocrine treatments that have been shown to render the mammary epithelium resistant to carcinogenesis. Preliminary data demonstrate that treatment with both estrogen and progesterone (E+P) are required for p53-dependent responses to DNA damage in the mammary epithelium. We propose that the mammary epithelium is rendered susceptible to carcinogenesis due to impaired p53 activity during specific periods of mammary gland development, but that specific endocrine stimuli serve to activate p53 function and mitigate this risk. The experiments outlined in this proposal will define the pathways by which treatment with E+P regulate p53 function in the mammary gland. Aim 1: The pathways that mediate the effects of E+P on p53 activity will be examined by determining the receptors that initiate the cascade (Aim 1.1), the transcriptional targets of E+P that transduce the signal (Aim 1.2), and the enzymes that act on p53 protein to render it responsive to DNA damage-induced stress signals (Aim 1.3). Aim 2: Mice bearing transplants of mammary epithelium that vary in p53 status (BALB/c-Trp53+/- vs BALB/c-Trp53-/-) will be used to determine whether hormonal treatments inhibit mammary tumors by p53-dependent mechanisms. Aim 3: The pathways necessary for E+P-dependent activation of p53 will be examined in whole organ cultures using drug inhibitors and mammary tissue from knockout mice to identify specific targets. Breast epithelial cell lines will be used to provide higher resolution analysis of the molecular mechanisms. Based on preliminary data, the effects of retinoic acid metabolism and TGF-beta signaling will be emphasized. The results will lead to identification of cellular mechanisms that regulate p53 function in the mammary epithelium. These pathways will provide novel targets for both treatment and prevention of breast cancer.
描述(由申请人提供):在p53通路中携带遗传缺陷的女性中患乳腺癌的极端风险揭示了p53在乳腺癌易感性中的特别重要性。我们的实验室已经证明,乳腺上皮中的p53肿瘤抑制蛋白的活性受激素调节。具体而言,p53活性在未经产小鼠的乳腺上皮中受损,但对已显示使乳腺上皮对致癌作用具有抗性的内分泌治疗有反应。初步数据表明,治疗与雌激素和孕激素(E+P)的p53依赖性反应,在乳腺上皮细胞的DNA损伤是必需的。我们建议,乳腺上皮细胞是由于受损的p53活性在特定时期的乳腺发育致癌,但特定的内分泌刺激激活p53功能,减轻这种风险。本提案中概述的实验将确定E+P治疗调节乳腺中p53功能的途径。目标1:通过确定启动级联反应的受体(目的1.1)、抑制信号的E+P转录靶点(目的1.2)和作用于p53蛋白使其响应DNA损伤诱导的应激信号的酶(目的1.3),将检查介导E+P对p53活性的影响的途径。目标二:携带p53状态不同的乳腺上皮移植物(BALB/c-Trp 53 +/- vs BALB/c-Trp 53-/-)的小鼠将用于确定激素治疗是否通过p53依赖性机制抑制乳腺肿瘤。目标3:将使用药物抑制剂和来自敲除小鼠的乳腺组织在整个器官培养物中检查p53的E+ P依赖性激活所必需的途径,以鉴定特定靶点。乳腺上皮细胞系将用于提供更高分辨率的分子机制分析。基于初步数据,将强调视黄酸代谢和TGF-β信号传导的影响。结果将导致识别的细胞机制,调节p53在乳腺上皮细胞的功能。这些途径将为乳腺癌的治疗和预防提供新的靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

D. Joseph Jerry其他文献

Exposure to oxybenzone during the perinatal period disrupts development of the male and female mouse mammary gland
  • DOI:
    10.1016/j.reprotox.2018.07.060
  • 发表时间:
    2018-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Klara Matouskova;D. Joseph Jerry;Laura N. Vandenberg
  • 通讯作者:
    Laura N. Vandenberg
Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer
  • DOI:
    10.1007/s10911-022-09522-w
  • 发表时间:
    2022-07-29
  • 期刊:
  • 影响因子:
    3.600
  • 作者:
    James L. Miller;Arianna P. Bartlett;Rebecca M. Harman;Prabin Dhangada Majhi;D. Joseph Jerry;Gerlinde R. Van de Walle
  • 通讯作者:
    Gerlinde R. Van de Walle
Estrogens, regulation of p53 and breast cancer risk: a balancing act
  • DOI:
    10.1007/s00018-009-0244-7
  • 发表时间:
    2010-01-13
  • 期刊:
  • 影响因子:
    6.200
  • 作者:
    D. Joseph Jerry;Karen A. Dunphy;Mary J. Hagen
  • 通讯作者:
    Mary J. Hagen

D. Joseph Jerry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('D. Joseph Jerry', 18)}}的其他基金

Disruption of parity-induced tumor suppressor pathways by xenoestrogen exposures
异雌激素暴露对胎次诱导的肿瘤抑制途径的破坏
  • 批准号:
    9304860
  • 财政年份:
    2015
  • 资助金额:
    $ 27.12万
  • 项目类别:
2010 Mammary Gland Biology GRC
2010年乳腺生物学GRC
  • 批准号:
    8074052
  • 财政年份:
    2010
  • 资助金额:
    $ 27.12万
  • 项目类别:
2010 Mammary Gland Biology GRC
2010年乳腺生物学GRC
  • 批准号:
    8271301
  • 财政年份:
    2010
  • 资助金额:
    $ 27.12万
  • 项目类别:
2010 Mammary Gland Biology GRC
2010年乳腺生物学GRC
  • 批准号:
    7905344
  • 财政年份:
    2010
  • 资助金额:
    $ 27.12万
  • 项目类别:
P53-dependent responses to toxicants in parous and nulliparous breast
经产和未产乳房对毒物的 P53 依赖性反应
  • 批准号:
    7627331
  • 财政年份:
    2007
  • 资助金额:
    $ 27.12万
  • 项目类别:
P53-dependent responses to toxicants in parous and nulliparous breast
经产和未产乳房对毒物的 P53 依赖性反应
  • 批准号:
    7289413
  • 财政年份:
    2007
  • 资助金额:
    $ 27.12万
  • 项目类别:
P53-dependent responses to toxicants in parous and nulliparous breast
经产和未产乳房对毒物的 P53 依赖性反应
  • 批准号:
    7494463
  • 财政年份:
    2007
  • 资助金额:
    $ 27.12万
  • 项目类别:
Genetic modifiers of mammary tumor susceptibility
乳腺肿瘤易感性的遗传修饰
  • 批准号:
    7559622
  • 财政年份:
    2005
  • 资助金额:
    $ 27.12万
  • 项目类别:
Genetic modifiers of mammary tumor susceptibility
乳腺肿瘤易感性的遗传修饰
  • 批准号:
    7359638
  • 财政年份:
    2005
  • 资助金额:
    $ 27.12万
  • 项目类别:
Genetic modifiers of mammary tumor susceptibility
乳腺肿瘤易感性的遗传修饰
  • 批准号:
    7679752
  • 财政年份:
    2005
  • 资助金额:
    $ 27.12万
  • 项目类别:

相似海外基金

A novel strategy targeting TP63 for breast cancer prevention
一种针对 TP63 预防乳腺癌的新策略
  • 批准号:
    10608150
  • 财政年份:
    2022
  • 资助金额:
    $ 27.12万
  • 项目类别:
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care
降低风险的药物可以改善儿童和青少年癌症幸存者的乳腺癌预防吗?
  • 批准号:
    10459788
  • 财政年份:
    2022
  • 资助金额:
    $ 27.12万
  • 项目类别:
A novel strategy targeting TP63 for breast cancer prevention
一种针对 TP63 预防乳腺癌的新策略
  • 批准号:
    10435255
  • 财政年份:
    2022
  • 资助金额:
    $ 27.12万
  • 项目类别:
Spatially informed interrogation of the high-risk breast for breast cancer prevention
对高风险乳房进行空间知情询问以预防乳腺癌
  • 批准号:
    473970
  • 财政年份:
    2022
  • 资助金额:
    $ 27.12万
  • 项目类别:
    Fellowship Programs
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care
降低风险的药物可以改善儿童和青少年癌症幸存者的乳腺癌预防吗?
  • 批准号:
    10675772
  • 财政年份:
    2022
  • 资助金额:
    $ 27.12万
  • 项目类别:
Proof-of-concept of time-restricted eating as a novel lifestyle intervention for breast cancer prevention
限时饮食作为预防乳腺癌的新型生活方式干预措施的概念验证
  • 批准号:
    460504
  • 财政年份:
    2021
  • 资助金额:
    $ 27.12万
  • 项目类别:
    Operating Grants
A Simulation Modeling Study to Support Personalized Breast Cancer Prevention and Early Detection in High-Risk Women
支持高危女性个性化乳腺癌预防和早期检测的模拟模型研究
  • 批准号:
    10201836
  • 财政年份:
    2021
  • 资助金额:
    $ 27.12万
  • 项目类别:
A Simulation Modeling Study to Support Personalized Breast Cancer Prevention and Early Detection in High-Risk Women
支持高危女性个性化乳腺癌预防和早期检测的模拟模型研究
  • 批准号:
    10371141
  • 财政年份:
    2021
  • 资助金额:
    $ 27.12万
  • 项目类别:
PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ENDPOINTS TASK ORDER: USE OF CARNOSIC ACID AND VIVOX40 FOR BREAST CANCER PREVENTION
预防临床前功效和中间生物标志物终点任务顺序:使用鼠尾草酸和 VIVOX40 预防乳腺癌
  • 批准号:
    10453429
  • 财政年份:
    2020
  • 资助金额:
    $ 27.12万
  • 项目类别:
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia
生物标志物可提高非典型增生女性乳腺癌预防的针对性
  • 批准号:
    10542756
  • 财政年份:
    2020
  • 资助金额:
    $ 27.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了